🇺🇸 MRK — Merck & Co., Inc.

Healthcare Compra
← Volver

Precio actual

150,33 USD

Máx. histórico

156,92

10 días

Caída desde máximo

-4,20%

Rango 52 semanas

77,58 – 156,92

Variación hoy

-1,32%

Cierre anterior

152,34

Rango de hoy

150,09 – 152,22

Volumen hoy

4.298.143

Información
Nombre completo
Merck & Co., Inc.
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
73.000
PER
122,22 (puede no estar actualizado)
Dividend yield
2,23% (puede no estar actualizado)
Precio objetivo analistas
148,73 USD (puede no estar actualizado)
Primera cotización
02/01/1962
Precio actualizado
hace 1 día
Sobre la empresa

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Dividendos repartidos Total últimos 12 meses: 3,3600 USD · Yield: 2,24%
Fecha de pago Importe por participación
12/03/2015 0,4294 USD
11/12/2014 0,4294 USD
11/09/2014 0,4198 USD
12/06/2014 0,4198 USD
13/03/2014 0,4198 USD
12/12/2013 0,4198 USD
12/09/2013 0,4103 USD
13/06/2013 0,4103 USD
13/03/2013 0,4103 USD
13/12/2012 0,4103 USD
13/09/2012 0,4008 USD
13/06/2012 0,4008 USD
13/03/2012 0,4008 USD
13/12/2011 0,4008 USD
13/09/2011 0,3626 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
01/03/2024 126,87 127,85 126,42 126,96 -0,15% 1,13% 6.023.400
29/02/2024 128,10 128,85 127,06 127,15 -0,81% 1,40% 11.246.100
28/02/2024 129,34 129,40 127,70 128,19 -0,65% 1,31% 5.697.200
27/02/2024 128,26 129,16 127,80 129,03 +0,15% 1,06% 4.780.200
26/02/2024 129,38 129,70 128,47 128,84 -0,47% 0,95% 5.158.400
23/02/2024 129,79 130,24 128,86 129,45 +0,15% 1,06% 5.177.400
22/02/2024 128,15 129,72 127,65 129,26 +0,89% 1,62% 6.517.400
21/02/2024 127,44 128,16 126,80 128,12 +0,59% 1,07% 4.849.200
20/02/2024 128,13 129,29 127,21 127,37 -0,33% 1,62% 6.952.800
16/02/2024 126,50 128,09 126,17 127,79 +0,99% 1,52% 6.266.800
15/02/2024 125,97 127,23 125,95 126,54 +0,57% 1,02% 5.756.700
14/02/2024 125,61 126,03 124,82 125,82 +0,31% 0,96% 6.622.400
13/02/2024 125,98 126,86 124,48 125,43 +0,07% 1,89% 7.273.400
12/02/2024 125,00 125,48 124,40 125,34 -0,09% 0,86% 5.257.400
09/02/2024 126,22 126,69 125,04 125,45 -0,92% 1,31% 7.891.200
08/02/2024 127,32 127,48 125,95 126,61 -0,67% 1,20% 6.308.300
07/02/2024 126,90 128,06 126,50 127,47 +0,47% 1,23% 6.742.800
06/02/2024 126,61 127,52 126,07 126,88 +0,55% 1,15% 6.153.000
05/02/2024 126,98 127,80 125,70 126,18 -0,18% 1,65% 8.027.700
02/02/2024 126,71 127,56 126,11 126,41 +0,02% 1,14% 10.175.600
01/02/2024 123,65 126,43 122,77 126,38 +4,64% 2,96% 11.650.700
31/01/2024 122,53 122,85 120,50 120,78 -0,72% 1,92% 10.779.000
30/01/2024 121,28 121,76 120,18 121,66 +0,31% 1,30% 7.469.500
29/01/2024 121,35 121,46 120,49 121,28 +0,38% 0,80% 9.138.200
26/01/2024 120,51 121,02 120,08 120,82 +0,57% 0,78% 8.300.300
25/01/2024 118,66 120,18 118,66 120,13 +1,05% 1,28% 6.689.800
24/01/2024 119,70 119,95 118,44 118,88 -0,80% 1,26% 5.859.900
23/01/2024 118,14 119,99 117,27 119,84 +0,34% 2,30% 6.501.400
22/01/2024 119,04 119,97 118,86 119,43 +0,45% 0,93% 8.786.200
19/01/2024 118,21 119,02 117,72 118,89 +0,30% 1,10% 7.605.600